

Dermira, Inc.  
Form 8-K  
March 02, 2017

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of**  
**the Securities Exchange Act of 1934**

**Date of report (date of earliest event reported): March 1, 2017**

**DERMIRA, INC.**

**(Exact name of registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction of**  
**incorporation or organization)**

**001-36668**  
**(Commission File Number)**

**27-3267680**  
**(I.R.S. Employer**  
**Identification Number)**

**275 Middlefield Road, Suite 150**

**Menlo Park, California**  
**(Address of Principal Executive Offices)**

**94025**  
**(Zip Code)**

**Registrant's telephone number, including area code: (650) 421-7200**

**Not Applicable**

**(Former Name or Former Address, if Changed Since Last Report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 1.01 Entry into a Material Definitive Agreement.**

On March 1, 2017, Dermira, Inc. (the *Company*) entered into an underwriting agreement (the *Underwriting Agreement*) with Leerink Partners LLC, as representative of the several underwriters named on Schedule II thereto (the *Underwriters*), pursuant to which the Company agreed to issue and sell an aggregate of 5,000,000 shares of its common stock (the *Shares*) to the Underwriters (the *Offering*). The Shares will be sold at a per share public offering price of \$33.70. Pursuant to the Underwriting Agreement, the Company also granted the Underwriters a 30-day option to purchase up to an additional 750,000 shares of its common stock. The Underwriting Agreement contains customary representations and warranties, conditions to closing, market standoff provisions, termination provisions and indemnification obligations, including for liabilities under the Securities Act of 1933, as amended. The Offering will be made pursuant to a shelf registration statement on Form S-3 (File No. 333-216331) that automatically became effective upon filing by the Company with the Securities and Exchange Commission (*SEC*) on February 28, 2017. The Company expects the Offering to close on March 7, 2017, subject to customary closing conditions.

The Company estimates that net proceeds from the Offering will be approximately \$157.7 million, after deducting the underwriting discounts and commissions and estimated Offering expenses, and assuming no exercise of the Underwriters' option to purchase additional shares. The Company currently intends to use the net proceeds from the Offering for: external and personnel-related expenses associated with the regulatory submissions for the Company's Cimzia and glycopyrronium tosylate product candidates; external and personnel-related research and development expenses associated with the development of and potential regulatory submission for the Company's olumacostat glasaretil product candidate; external and personnel-related commercialization expenses associated with the potential launches of the Company's product candidates, including the establishment or expansion of the Company's sales, marketing, medical affairs, quality and supply chain functions and activities; and working capital, capital expenditures and other general corporate purposes. Additionally, the Company may use a portion of the net proceeds from the Offering to expand the Company's current business by in-licensing or acquiring, as the case may be, commercial products, product candidates, technologies, compounds, other assets or complementary businesses, using cash or shares of the Company's common stock. However, the Company has no current commitments or obligations to do so.

The foregoing description of the Underwriting Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Underwriting Agreement. A copy of the Underwriting Agreement is filed with this Current Report on Form 8-K as Exhibit 1.1 and is incorporated herein by reference.

A copy of the opinion of Fenwick & West LLP, relating to the validity of the Shares in connection with the Offering, is filed with this Current Report on Form 8-K as Exhibit 5.1.

**Item 8.01. Other Events.**

On March 1, 2017, the Company issued a press release, announcing the pricing of the Offering. A copy of the press release is filed with this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits.

**Exhibit**

**Number Description of Exhibit**

Edgar Filing: Dermira, Inc. - Form 8-K

- 1.1 Underwriting Agreement dated March 1, 2017.
- 5.1 Opinion of Fenwick & West LLP.
- 23.1 Consent of Fenwick & West LLP (contained in Exhibit 5.1).
- 99.1 Press release dated March 1, 2017.

## **Forward-Looking Statements**

This Current Report on Form 8-K contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein that do not describe historical facts, including, but not limited to, statements regarding the anticipated use of proceeds of the Offering and the timing of completion of the Offering, are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements. Such risks and uncertainties include, among others, the risks identified in the Company's filings with the SEC, including those described under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2016, as well as those discussed in the prospectus supplement related to the Offering, the accompanying prospectus to the prospectus supplement related to the Offering, the documents incorporated by reference herein and therein, any related free writing prospectus, and subsequent filings with the SEC. Any of these risks and uncertainties could materially and adversely affect the Company's results of operations, which would, in turn, have a significant and adverse impact on the Company's stock price. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made or to reflect the occurrence of unanticipated events.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Dermira, Inc.**

Date: March 1, 2017

By: /s/ Andrew L. Guggenime

Name: Andrew L. Guggenime

Title: Chief Operating Officer and Chief Financial  
Officer

**EXHIBIT INDEX**

**Exhibit**

<b>Number</b>	<b>Description of Exhibit</b>
1.1	Underwriting Agreement dated March 1, 2017.
5.1	Opinion of Fenwick & West LLP.
23.1	Consent of Fenwick & West LLP (contained in Exhibit 5.1).
99.1	Press release dated March 1, 2017.